Pharmaceutical Technology

APRIL 5, 2023

Under the collaboration, Absci’s generative AI drug creation platform will use M2GEN’s ORIEN AVATAR (AVATAR), a clinical and molecular data set, to speed up the creation of therapies for a range of malignancies and patient profiles.

Development 130

Development Bioinformatics Drugs Immune Response 130

XTalks

DECEMBER 3, 2024

This technology, already approved by the US Food and Drug Administration (FDA) for glioblastoma and mesothelioma , and most recently for metastatic non-small cell lung cancer (NSCLC), harnesses electric fields to disrupt cancer cell division. Novocure’s broader pipeline underscores the versatility of TTFields therapy.

Trials 105

Trials Immune Response Clinical Trials Clinical Trials 105

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.

Development 264

Development Antibody Immune Response Production 264

Pharmaceutical Technology

NOVEMBER 11, 2022

The vaccine elicited a robust immune response against several variants in registrational trials conducted when the Omicron variant of the virus was dominant. According to advance purchase agreements in place, vaccine shipments are ready to be supplied to countries in Europe. .

Vaccination 246

Vaccination Vaccine Immune Response Protein 246

World of DTC Marketing

AUGUST 21, 2020

But scientists in the emerging field of immunometabolism are finding obesity also interferes with the body’s immune response, putting obese people at greater risk of infection from pathogens such as influenza and the novel coronavirus. An analysis is predicting that by 2030, 48.9% will be severely obese. .

Immune Response 238

Immune Response Vaccine Vaccination Scientist 238

XTalks

NOVEMBER 5, 2024

Its lead candidate, PL-14, targets nasal allergies and is scheduled for US Food and Drug Administration (FDA) submission via the 510(k) pathway, with preclinical trials expected to start in the second quarter of 2025 and pivotal trials by the end of 2025.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

Worldwide Clinical Trials

OCTOBER 14, 2024

Scientists now use cutting-edge techniques, including biological therapies that target specific immune system components and precision medicine approaches that personalize treatment plans based on a patient’s genetic profile.

Research 147

Research Clinical Trials Clinical Trials Immune Response 147

Drug Patent Watch

DECEMBER 9, 2024

Additionally, the immunogenicity of biosimilars, which is the ability of the drug to trigger an immune response, can be highly variable and impact the safety and efficacy of the drug.

Clinical Trials 97

Clinical Trials Clinical Trials Immune Response Production 97

Pharmaceutical Technology

JUNE 16, 2023

Avenge Bio has obtained orphan drug designation from the US Food and Drug Administration (FDA) for its AVB-001 to treat mesothelioma patients. This triggers a systemic immune response, enabling the treatment of previously intractable cancers.

Drugs 130

Drugs Immune Response Clinical Development Trials 130

Pharmaceutical Technology

JANUARY 9, 2023

Immunome president and CEO Purnanand Sarma said: “AbbVie shares our vision of harnessing the power of the human immune response to yield novel and first-in-class therapeutics that represent a shift in the cancer discovery paradigm.

Engineer 130

Engineer Antibody Drugs Immune Response 130

Camargo

JULY 27, 2021

When developing a clinical development program for these increasingly popular therapies, it is important that sponsors use modeling and pharmacokinetic (PK) analysis to evaluate parameters that can be measured while dosing with gene therapy drugs, to characterize exposure-response data and inform rational dosing.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

XTalks

NOVEMBER 15, 2024

Syros Pharmaceuticals announced that its cancer drug tamibarotene failed to meet its primary endpoint in the SELECT-MDS-1 Phase III trial. These RXR receptors play a key role in regulating transcription pathways involved in inflammation and immune responses, among other cancer hallmarks, to modulate the tumor microenvironment.

Trials 105

Trials HR Immune Response FDA Approval 105

Worldwide Clinical Trials

OCTOBER 14, 2024

Scientists now use cutting-edge techniques, including biological therapies that target specific immune system components and precision medicine approaches that personalize treatment plans based on a patient’s genetic profile.

Research 130

Research Clinical Trials Clinical Trials Immune Response 130

World of DTC Marketing

DECEMBER 29, 2020

Once introduced into the human body, the protein-making machinery uses this genetic material in our cells to churn out the coronavirus “spike protein,” triggering an immune response. For the COVID-19 vaccine, the Food and Drug Administration (FDA) set up rigorous standards for vaccine developers to meet.

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307

Medical Xpress

FEBRUARY 2, 2023

Patients with glioblastoma—the deadliest type of primary brain tumor—may potentially benefit from immunotherapy medications called immune checkpoint inhibitors that stimulate an immune response against cancer cells.

Immune Response 98

Immune Response Drugs 98

XTalks

DECEMBER 30, 2024

has announced promising Phase IIb results for cenerimod, an investigational drug targeting immune system dysfunction in moderate-to-severe systemic lupus erythematosus (SLE). SLE is an autoimmune disease where the immune system attacks healthy tissues, causing inflammation, pain and potential organ damage. Viatris Inc.

Immune Response 52

Immune Response Gene Expression Drugs Trials 52

Pharmaceutical Technology

DECEMBER 16, 2022

The example of rituximab, originally a cancer drug, now used for lupus, has shown the potential of adopting cancer medications for lupus. Furthermore, drug-free remission was maintained during longer follow-up and even beyond the reappearance of B cells.

Immune Response 147

Immune Response Marketing Antibody Trials 147

XTalks

NOVEMBER 12, 2024

Thus, to address drug-resistant infections, pharma and biotech companies are developing novel treatments such as bacteriophage therapies, immunomodulators and monoclonal antibodies. These therapies work by controlling excessive inflammatory responses in the lungs.

Bacteria 110

Bacteria Life Science Vaccination Vaccine 110

Scienmag

SEPTEMBER 15, 2020

Scientists at Sanford Burnham Prebys Medical Discovery Institute have received a $3 million grant from the National Institutes of Health (NIH) to study how SARS-CoV-19 weakens the immune system–and identify drugs to help infected […].

Immune Response 60

Immune Response Scientist Drugs Allergies 60

Scienmag

DECEMBER 9, 2021

When the body attempts to fight off an infection, immune cells called neutrophils may shoot out spider web-like networks of toxic proteins to help contain the invaders.

Immune Response 60

Immune Response Containment Protein Regulation 60

STAT News

DECEMBER 23, 2022

Food and Drug Administration approved a new treatment for patients with follicular lymphoma, a slow-growing type of blood cancer, said Genentech , its maker and a subsidiary of Roche. In a clinical trial, 60% of patients with follicular lymphoma treated with Lunsumio achieved a complete response. Happy holidays from all of us.

FDA Approval 98

FDA Approval Immune Response Drugs Research 98

STAT News

DECEMBER 13, 2022

Medicines that reshape or tamp down immune responses may be life-changing for patients with cancer and autoimmune disorders, but in some cases they can awaken a dormant virus and unleash a deadly brain disease. A new study suggests that the root of the problem is buried in our genetic code.

Genetics 105

Genetics Immune Response Gene Drugs 105

NY Times

APRIL 14, 2022

Pfizer and BioNTech will soon ask the Food and Drug Administration for emergency authorization of Covid booster doses for that age group, the companies said.

Immune Response 55

Immune Response Drugs Vaccination Vaccine 55

XTalks

DECEMBER 20, 2024

The US Food and Drug Administration (FDA) has approved Celltrions Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for the treatment of several immune-mediated diseases. By blocking these inflammatory pathways, it helps manage overactive immune responses in conditions like psoriasis and Crohns disease.

FDA Approval 52

FDA Approval Immune Response Antibody Marketing 52

Medical Xpress

JANUARY 10, 2023

This is because to survive a serious infection it is not enough to get rid of the infectious agent, which is currently done with relative effectiveness; it is also necessary to limit the damage these and the immune response cause to the organs.

Immune Response 89

Immune Response Drugs Research 89

Pharmaceutical Technology

OCTOBER 25, 2022

The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Imjudo (tremelimumab) plus Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), a kind of liver cancer.

Protein 173

Protein Immune Response Antibody FDA Approval 173

NY Times

MAY 11, 2022

Antibody levels rose in the children who received it, suggesting the vaccine protects against infection. But the data were gathered before the arrival of Omicron.

Immune Response 62

Immune Response Vaccination Vaccine Antibody 62

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. “The authors acknowledge certain limitations of the study, including small numbers of participants.

Vaccination 116

Vaccination Vaccine Immune Response Development 116

The Pharma Data

JULY 29, 2021

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Immune Response 52

Immune Response Development Medicine Drugs 52

Pharmaceutical Technology

JULY 12, 2022

Health Canada has accepted to review Arcutis Biotherapeutics’ New Drug Submission (NDS) for roflumilast cream 0.3% (ARQ-151) to treat plaque psoriasis in adult and adolescent patients. A validated target in dermatology, PDE4 is an enzyme that induces overactive immune responses.

Dermatology 162

Dermatology Immune Response Trials Clinical Trials 162

Pharmaceutical Technology

OCTOBER 6, 2022

BioLink Life Sciences president Deanna Nelson said: “We are very excited to repurpose a drug that has an established safety record over 20 years of use, is conveniently given twice daily by mouth to both inpatients and outpatients and is highly cost-effective. “If

Development 162

Development Life Science Immune Response Trials 162

pharmaphorum

DECEMBER 17, 2020

Siltuximab is an IL-6 inhibiting drug that was originally developed and marketed by the Johnson & Johnson’s Janssen unit for the rare disorder idiopathic multicentric Castleman’s disease. EUSA Pharma bought global rights to the drug from Janssen in $115 million. Feature image courtesy of Rocky Mountain Laboratories/NIH.

Drugs 105

Drugs Immune Response Trials Clinical Trials 105

Scienmag

MAY 28, 2021

The drug diABZI — which activates the body’s innate immune response — was highly effective in preventing severe COVID-19 in mice that were infected with SARS-CoV-2, according to scientists in the Perelman School of Medicine at the University of Pennsylvania.

Immune Response 71

Immune Response Drugs Scientist Research 71

Medical Xpress

NOVEMBER 14, 2022

An immune response that likely evolved to help fight infections appears to be the mechanism that drives human immunodeficiency virus (HIV) into a latent state, lurking in cells only to erupt anew, researchers at Duke Health report.

Immune Response 75

Immune Response Drugs Research 75

pharmaphorum

JULY 5, 2021

The reason none of them can say with certainty whether or not they are truly safe is because everyone’s immune response is unique to that individual. In some cases, we see significant variations among similarly aged people with similar health histories when it comes to their individual responses to the virus or vaccines.

Immune Response 105

Immune Response Antibody Vaccination Vaccine 105

NY Times

MARCH 23, 2022

The company said the vaccine produced a strong immune response in children younger than 6, but proved only about 40 percent effective in preventing symptomatic Covid-19.

Vaccination 94

Vaccination Vaccine Immune Response Clinical Trials 94

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . We believe that prior immunity in humans may be important for a robust immune response to intranasal dosing.”

Vaccination 98

Vaccination Vaccine Trials Immune Response 98